Treatment using ipilimumab, a CTLA-4 targeting antibody, shows restoration of tumor immunity at the priming phase and extends survival in some patients, conversely anti-PD-1/PD-L1 antibodies seem to affect the malignancy by returning immune function in the tumor microenvironment [7,8]. Here, PDCD1 is linked to neoplasm.